A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Curr Opin Lipidol. 2026 Apr 7. doi: 10.1097/MOL.0000000000001040. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Janus kinase (JAK) inhibitors have emerged as potent anti-inflammatory drugs and are prescribed in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). However, cardiovascula

K Katherine Muñoz Ayala

Fundamentals of Acute Pericarditis: State of the Art

Arq Bras Cardiol. 2026 Apr 17;123(2):e20240572. doi: 10.36660/abc.20240572. eCollection 2026.ABSTRACTAcute pericarditis is an inflammation of the pericardium, the lining that surrounds the heart. It is the most common inflammatory heart condition. The disease frequently affects young adults and can

G Gabriel de Moraes Mangas

Cost-Effectiveness of Therapies for Heart Failure in Brazil: A Systematic Review

Arq Bras Cardiol. 2026 Mar;123(3):e20250712. doi: 10.36660/abc.20250712.ABSTRACTHeart failure (HF) is among the leading causes of cardiovascular mortality in Brazil. In 2021, costs attributable to HF exceeded R$ 22 billion in the Brazilian Unified Health System (SUS). The incorporation of new therap

G Guilherme Augusto Reissig Pereira

Dextrocardia: Understanding Complex Anatomy to Treat This Disorder

Cardiol Rev. 2026 Apr 22. doi: 10.1097/CRD.0000000000001273. Online ahead of print.ABSTRACTDextrocardia occurs in approximately 1 in 10,000 live births and is frequently dismissed as an incidental anatomic variant, particularly when accompanied by situs inversus totalis and a structurally normal hea

N Nabeel Sami

Programming peripheral artery disease in diabetes

Reprogrammed TREM2^(+) macrophages drive nonresolving inflammation in peripheral artery disease associated with type 2 diabetes (Malhi et al., this issue).Sci Transl Med. 2026 Apr 22;18(846):eaef8756. doi: 10.1126/scitranslmed.aef8756. Epub 2026 Apr 22.ABSTRACTReprogrammed TREM2+ macrophages drive n

M Michael D Chang